{
  "docId": "019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "docSlug": "be407bbae8f9e005c3f7268aea2b4f13",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 34 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 34,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "Data shows p-values of 0.005 and <0.001 for treated groups, indicating significant biomarker reduction.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2fc9-715d-b6e1-faa3fd3ed1eb/17",
  "deckHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "deckJsonHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb.json",
  "deckAnchorHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.6,
        "x": 0.33,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Neuroinflammation PgJ2 charts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b07b445-180d-473a-a17d-e88fb2904e05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.6,
        "x": 0.33,
        "y": 0.18
      },
      "kind": "chart",
      "text": "TDP-43 Accumulation charts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fbdb033-8db2-4a86-aeb9-9ceb0907b529",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.96,
        "x": 0.02,
        "y": 0.94
      },
      "kind": "other",
      "text": "Phase 2a Results navigation bar",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7359b51-2f9d-4fbb-9ba4-7a60cd07fbb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.07,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Treated: Patients from NST002 Phase 2a clinical trial who received PrimeC (intermediate formulation). Non-treated: Matched patients on standard of care",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d71f2627-68f8-4c7f-8e0f-a5b5801017ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "PrimeC Significantly Altered Key ALS Biomarkers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ff45950-88e9-46f0-b458-5da0f31afcc4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "5fec0e20-c8e4-43c6-ab84-049a28a39a4a",
      "evidence": "The line charts are simple and clear, with a straightforward message.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 34,
      "from": 5,
      "beatId": "e49a51a7-5d8f-48c6-bbde-aebd1ab25027",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a potential solution to the problem of limited ALS treatment options.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 18,
      "from": 13,
      "beatId": "634ec05e-3498-46b7-b4f3-93263be96284",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents evidence and proof of PrimeC's effectiveness in clinical trials.",
      "position": 3,
      "confidence": 0.9,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 34,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "c317ff20-e462-4b87-8745-365a96908ee6",
      "evidence": "The document outlines the development process and clinical trials for PrimeC.",
      "position": 1,
      "objective": "What are the key tasks that need to be done to develop PrimeC as a treatment for ALS?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.8,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}